Human sTRAIL Receptor-2, also known as DR5 (Death Receptor-5), is a member of the TNF receptor family. Human sTRAIL Receptor-2 is a 14.9kD protein containing 133 amino acid residues comprising the extracellular domain of TRAIL Receptor-2. Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently (1-7). Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-kB.
Biological Activity:
Determined by its inhibitory effect of IL-8 produced in human PBMC (peripheral blood mononuclear cells) by human sTRAIL/Apo2L. 50% inhibition (100ng/ml of sTRAIL/Apo2L) was reached using a concentration of 1000ng/ml of sTRAIL Receptor-2.
AA Sequence:
MESALITQQD LAPQQRVAPQ QKRSSPSEGL CPPGHHISED GRDCISCKYG QDYSTHWNDL LFCLRCTRCD SGEVELSPCT TTRNTVCQCE EGTFREEDSP EMCRKCRTGC PRGMVKVGDC TPWSDIECVH KES
Storage and Stability:
Lyophilized powder may be stored at -20 degrees C. Reconstitute to nominal volume by adding sterile ddH2O, carrier protein. Aliquot and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Country of Origin: USA
Quick Search
Products 
